Search Results

You are looking at 161 - 170 of 1,293 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Ashwin Rao, Nicole E. Rich, Jorge A. Marrero, Adam C. Yopp, and Amit G. Singal

, characteristic imaging [LI-RADS 5] or histopathologic confirmation). 25 We excluded patients (1) with liver masses without characteristic imaging or histology, (2) for whom the date of HCC presentation and/or diagnosis could not be ascertained from the

Full access

Alimujiang Wushou, Meng Wang, Feiluore Yibulayin, Lei Feng, Meng-meng Lu, Yuan Luo, Hui Liu, and Zhi-cheng Yang

resection of the primary tumor, in consideration of postoperative recurrence and poor prognosis due to the high rate of occult cervical metastasis in early OSCC. 13 Because of the lack of consensus in characteristics, study populations, and patient

Full access

Laura Bourdeanu, Thehang Luu, Norma Baker, Suzanne Swain-Cabriales, Cathie T. Chung, Joanne Mortimer, Arti Hurria, Sandra Helton, David Smith, Betty Ferrell, Gloria Juarez, and George Somlo

.8% Hispanic, 7.8% African American, and 10.5% Asian. The characteristics of the study population are shown in Table 2 . Patients experienced a range of 16- to 77-week delays (median, 24 weeks) to initiating chemotherapy treatment. For 75% of patients, the

Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff

, Patient Characteristics, and Treatment Identification This study identified all women older than 65 years diagnosed with ovarian cancer (n=26,379) in SEER cancer registries from January 1, 1995, to December 31, 2007. Women were excluded if they had a

Full access

Julie Hallet, Calvin Law, Simron Singh, Alyson Mahar, Sten Myrehaug, Victoria Zuk, Haoyu Zhao, Wing Chan, Angela Assal, and Natalie Coburn

the burden of cancer on mortality for patients with NETs remains scarce. NETs are a heterogeneous malignancy with variable biologic, clinical, and prognostic characteristics. There is an evolving need to adapt treatment plans to their unique biology

Full access

Reith R. Sarkar, Katherine E. Fero, Daniel M. Seible, Neil Panjwani, Rayna K. Matsuno, and James D. Murphy

. Analyses were conducted using SAS 9.4 (SAS Institute Inc). Results Cohort Characteristics Of the 21,500 patients in the study cohort, 11,298 (52.5%) presented with metastatic disease, 3,092 (14.4%) were in the resectable group, and 7,110 (33.1%) were in the

Full access

Ryan D. Nipp, Leah L. Thompson, Brandon Temel, Charn-Xin Fuh, Christine Server, Paul S. Kay, Sophia Landay, Daniel E. Lage, Lara Traeger, Erin Scott, Vicki A. Jackson, Nora K. Horick, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

believed prohibited informed consent or study participation. Study Measures Sociodemographic and Clinical Characteristics Participants completed a demographic questionnaire to report their race, relationship status, work status, education level, annual

Full access

Michael Xiang and Elizabeth A. Kidd

-Medicare linkage, patient follow-up was through December 2014. Statistical Analysis Baseline characteristics were compared using the chi-square or Wilcoxon rank-sum test. Multivariable logistic regression was used to identify predictors for receiving cisplatin

Full access

Rebecca M. Shulman, David S. Weinberg, Eric A. Ross, Karen Ruth, Glenn F. Rall, Anthony J. Olszanski, James Helstrom, Michael J. Hall, Julia Judd, David Y.T. Chen, Robert G. Uzzo, Timothy P. Dougherty, Riley Williams, Daniel M. Geynisman, Carolyn Y. Fang, Richard I. Fisher, Marshall Strother, Erica Huelsmann, Sunil Adige, Peter D. Whooley, Kevin Zarrabi, Brinda Gupta, Pritish Iyer, Melissa McShane, Hilario Yankey, Charles T. Lee, Nina Burbure, Lauren E. Laderman, Julie Giurintano, Samuel Reiss, and Eric M. Horwitz

extended to 90 days before the first vaccine dose. Early symptom onset was defined as an adverse event within 24 hours of vaccination. Baseline characteristics of the study population were tabulated separately for patients without cancer, unselected

Full access

Smith Giri, Mustafa Al-Obaidi, Alice Weaver, Kelly M. Kenzik, Andrew McDonald, Deanna Clark, Crystal Young-Smith, Ravi Paluri, Lakshmin Nandagopal, Olumide Gbolahan, Mackenzi Pergolotti, Smita Bhatia, and Grant R. Williams

for GA impairment and construction of the CARE Frailty Index are provided in supplemental eAppendices 1 and 2 . Statistical Analysis We compared baseline characteristics between the 3 age groups (60–64, 65–74, and ≥75 years) using appropriate